Название продукции:(R)-2-methylpropane-2-sulfinamide
IUPAC Name:(R)-2-methylpropane-2-sulfinamide
- CAS:196929-78-9
- Молекулярная формула:C4H11NOS
- Чистота:99%
- Номер в каталоге:CM112195
- Молекулярная масса:121.2
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:196929-78-9
- Молекулярная формула:C4H11NOS
- Точка плавления:-
- Smiles-код:CC([S@](N)=O)(C)C
- Плотность:
- Номер в каталоге:CM112195
- Молекулярная масса:121.2
- Точка кипения:
- Номер Mdl:MFCD05861479
- Хранение:Keep in a tight container and store at 2°C~8°C
Column Infos
- Nitrogen Compounds
- Nitrogen compounds can be classified as mineral or organic. Mineral compounds are essentially formed by the ammonium ion (NH4+), which is generated when ammonium salts are dissolved in water. Organic compounds, in contrast, are carbon and hydrogen compounds that contain a nitrogen atom. All organic nitrogen-containing compounds can be considered as derivatives of ammonia in which one or more hydrogen atoms are substituted by hydrocarbon radicals.
- Repotrectinib
- Repotrectinib receives approval for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) from the U.S. FDA on November 15, 2023. ROS1 gene is altered in about 1-2% of patients with NSCLC. ROS1-positive lung cancer tends to be aggressive and can spread to the brain and the bones.
Repotrectinib is a highly potent and differentiated small molecule TKI that binds inside the ATP pocket, and is active against both wild-type and resistant mutations, including solvent front and gatekeeper mutations. Repotrectinib is expected to enter the U.S. market in mid-December 2023.
- Olutasidenib
- Rigel announces publication of data on REZLIDHIA(Olutasidenib) in post-venetoclax patients with mutant IDH1 AML in Leukemia & Lymphoma.
REZLIDHIA (Olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1), in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.